sections

Thursday, 21 February 2019

Upfront

Sort by: Newest firstOldest firstA-ZZ-A

  • Posturing in Pakistan

    The IMF’s warning earlier this year that China’s emergence as the world’s biggest bilateral creditor could cause problems in future debt reckonings is finally catching the attention of its largest shareholder, the US.

  • Bad medicine

    Even in the new-fangled world of biotechnology, there is no such thing as a panacea. Ascletis Pharma, the first biotech company to go public under Hong Kong’s new listing rules, has done more harm than good.

  • Summer heat

    This summer is proving unusually hot for Asia’s capital markets – and it’s nothing to do with the record temperatures in parts of Japan.

  • India's bond chase

    India is taking another step along the path towards a vibrant corporate bond market. It needs to get there, quickly.

  • Project: impossible

    Asia’s first securitisation of project finance loans is cause for celebration. Keeping the party going, however, will be another story.

  • Strained connections

    Last week’s spat over the Stock Connect link between Hong Kong and China has dredged up some uncomfortable questions over the future of the parallel markets. It needn’t have.

  • Xiaomi's reboot

    What a relief. Xiaomi’s first week as a listed company has drawn a line under the recent run of shaky IPOs from China’s technology sector – but it could have been very different.

  • Public pressure

    In markets this bad, it may be better simply to stay away. That, at least, is the message from the latest US dollar high-yield bond from China’s property sector.

  • Global clout

    Strange as it sounds, global banks may do better in Asia when times are tough.

  • High stakes

    At some point, Asian high-yield bonds will become an enormous buying opportunity. Right now, however, it would take a brave fund manager to make that bet.